Breztri Aerosphere side effects: What they are and how to manage them
Drugs Versus Bugs: In Pursuit Of The Persistent Predator Mycobacterium Tuberculosis
Boshoff, H. I. M. & Barry 3rd, C. E. Tuberculosis-metabolism and respiration in the absence of growth. Nature Rev. Microbiol. 3, 70–80 (2005).
Russell, D. G. Who puts the tubercle in tuberculosis? Nature Rev. Microbiol. 5, 39–47 (2007).
Stewart, G. R., Roberston, B. D. & Young, D. B. Tuberculosis: a problem with persistence. Nature Rev. Microbiol. 1, 97–105 (2003). Focuses on the biology of persistence in mycobacteria.
Janin, Y. L. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479–2513 (2007). Discusses antitubercular small molecules, from early discovery compounds to approved drugs.
Ginsberg, A. M. & Spigelman, M. Challenges in tuberculosis drug research and development. Nature Med. 13, 290–294 (2007). An enlightening discussion of the current hurdles in TB drug discovery.
Williams, K. J. & Duncan, K. Current strategies for identifying and validating targets for new treatment-shortening drugs for TB. Curr. Mol. Med. 7, 297–307 (2007). An informative exposition that focuses on drug-discovery strategies.
Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727–730 (2002).
Cheng, A. C. Et al. Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnol. 25, 71–75 (2007).
Boshoff, H. I. M. Et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism. J. Biol. Chem. 279, 40174–40184 (2004).
Andries, K. Et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005).
Manjunatha, U. H. Et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431–436 (2006).
Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B. & Guilhot, C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol. Microbiol. 34, 257–267 (1999).
Cox, J. S., Chen, B., McNeil, M. & Jacobs, W. R. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79–83 (1999).
Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc. Natl Acad. Sci. USA 2001, 12712–12717 (2001).
Lamichane, G. Et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 12, 7213–7218 (2003).
Ehrt, S. Et al. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33, e21 (2005).
Carroll, P., Muttucumaru, D. G. & Parish, T. Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl. Environ. Microbiol. 71, 3077–3084 (2005).
Blokpoel, M. C. Et al. Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res. 33, e22 (2005).
Argyrou, A., Jin, L., Siconilfi-Baez, L., Angeletti, R. H. & Blanchard, J. S. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 45, 13947–13953 (2006).
Argyrou, A., Vetting, M. W., Aladegbami, B. & Blanchard, J. S. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nature Struct. Mol. Biol. 13, 408–413 (2006).
Nopponpunth, V., Sirawaraporn, W., Greene, P. J. & Santi, D. V. Cloning and expresion of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli. J. Bacteriol. 181, 6814–6821 (1999).
Rengarajan, J. Et al. The folate pathway is a target for resistance to the drug para-aminosalicyclic acid (PAS) in mycobacteria. Mol. Microbiol. 53, 275–282 (2004).
Vilcheze, C. Et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nature Med. 12, 1027–1029 (2006).
Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855–861 (2004).
Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nature Rev. Drug Discov. 5, 941–955 (2006).
Lee, R. E. Et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5, 172–187 (2003). Demonstrates a combinatorial chemistry expansion around ethambutol that was paired with a functional-assay approach to produce novel chemical entities that modulate mycobacterial cell-wall biosynthesis, including SQ109.
Johnson, D. E. & Rodgers, A. D. Computational toxicology: heading toward more relevance in drug discovery and development. Curr. Opin. Drug Discov. Devel. 9, 29–37 (2006).
Pearl, G. M., Livingston-Carr, S. & Durham, S. K. Integration of computational analysis as a sentinel tool in toxicological assessments. Curr. Top. Med. Chem. 1, 247–255 (2001).
Goldman, R. Et al. In Annual Conference on Antimicrobial Resistance (National Foundation for Infectious Diseases, Bethesda, 2006).
Alland, D., Steyn, A. J., Weisbrod, T., Aldrich, K. & Jacobs, W. R. Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182, 1802–1811 (2000).
Qureshi, N., Sathyamoorthy, N. & Takayama, K. Biosynthesis of C30 to C56 fatty acids by an extract of Mycobacterium tuberculosis H37Ra. J. Bacteriol. 157, 46–52 (1984).
Rozwarski, D. A., Vilchéze, C., Sugantino, M., Bittman, R. & Sacchettini, J. C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 274, 15582–15589 (1999).
Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591–593 (1992).
Muñoz-Elías, E. J. & McKinney, J. D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nature Med. 11, 638–644 (2005).
Sharma, V. Et al. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nature Struct. Biol. 7, 663–668 (2000).
White, E. L. Et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J. Biomol. Screen. 12, 100–105 (2007).
Bogatcheva, E. Et al. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem. 49, 3045–3048 (2006).
Murillo, A. C. Et al. High throughput crystallography of TB drug targets. Infect. Disord. Drug Targets 7, 127–139 (2007). Discusses the use of X-ray crystallography to catalyze TB drug-discovery efforts by the elucidation of the structures of essential M. Tuberculosis gene products.
Bajorath, J. Integration of virtual and high-throughput screening. Nature Rev. Drug Discov. 1, 882–894 (2002).
Shoichet, B. K. Virtual screening of chemical libraries. Nature 432, 862–865 (2004). Provides a good introduction to virtual screening using examples from drug discovery.
Shoichet, B. K., McGovern, S. L., Wei, B. & Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 6, 439–446 (2002).
Manetti, F. Et al. Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of Mycobacterium tuberculosis. ChemMedChem 1, 973–989 (2006).
García-García, A. Et al. Search of chemical scaffolds for novel antituberculosis agents. J. Biomol. Screen. 10, 206–214 (2005).
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
Agrawal, H., Kumar, A., Bal, N. C., Siddiqi, M. I. & Arora, A. Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett. 17, 3053–3058 (2007).
Parish, T. & Stoker, N. G. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148, 3069–3077 (2002).
Hediger, M. E. Design, synthesis, and evaluation of aza inhibitors of chorismate mutase. Bioorg. Med. Chem. 15, 4995–5010 (2004).
Lin, T. W. Et al. Structure-based inhibitor design of ACCD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 3072–3077 (2006).
Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007).
Dessen, A., Quemard, A., Blanchard, J. S., Jacobs, W. R. Jr & Sacchettini, J. C. Crystal structure and function of the isoniazid target of M. Tuberculosis. Science 267, 1638–1641 (1995).
Kuo, M. R. Et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J. Biol. Chem. 278, 20851–20859 (2003).
Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R. Jr & Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98–102 (1998).
Wang, F. Et al. Mechanism of thionamide drug action against tuberculosis and leprosy. J. Exp. Med. 204, 73–78 (2007).
Sullivan, T. J. Et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1, 43–53 (2006).
Tsukamura, M., Nakamura, E., Yoshii, S. & Amano, H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131, 352–356 (1985).
Aubry, A. Et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50, 104–112 (2006).
Veziris, N. Et al. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur. J. Clin. Microbiol. Infect. Dis. 26, 423–425 (2007).
Cole, S. T. Et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544 (1998). Determined the genome of M. Tuberculosis H37Rv.
Takiff, H. E. Et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl Acad. Sci. USA 9, 362–366 (1996).
Cynamon, M., Sklaney, M. R. & Shoen, C. Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J. Antimicrob. Chemother. 60, 429–432 (2007).
Spigelman, M. K. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196, S28–S34 (2007).
Cricchio, R., Arioli, V. & Lancini, G. C. Hydrazones of 3-formylrifamycin SV. I — hydrazones with N-amino-N′-substituted piperazines: synthesis, antibacterial activity and other biological properties. Farmaco [Sci] 30, 605–619 (1975).
Arioli, V. Et al. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J. Antibiot. (Tokyo) 34, 1026–1032 (1981).
Bemer-Melchior, P., Bryskier, A. & Drugeon, H. B. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 46, 571–575 (2000).
Dickinson, J. M. & Mitchison, D. A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68, 113–118 (1987).
Burman, W. J., Gallicano, K. & Peloquin, C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327–341 (2001).
Yamane, T. Et al. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. (Tokyo) 41, 148–155 (1993).
Fuji, K., Saito, H., Tomioka, H., Mae, T. & Hosoe, K. Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob. Agents Chemother. 39, 1489–1492 (1995).
Hirata, T. Et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39, 2295–2303 (1995).
Klemens, S. P. & Cynamon, M. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 40, 298–301 (1996).
Dietze, R. Et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 45, 1972–1976 (2001).
Mae, T. Et al. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica 28, 759–766 (1998).
Burman, W. J. & Jones, B. E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am. J. Respir. Crit. Care Med. 164, 7–12 (2001).
Report No. TDR/PRD/TB/03.1W (World Health Organization, Geneva, 2003).
Shepherd, R. G. & Wilkinson, R. G. Antituberculous agents. II. N,N′-diisopropylethylenediamine and analogs. J. Med. Pharm. Chem. 5, 823–835 (1962).
Wilkinson, R. G., Cantrall, M. B. & Shepherd, R. G. Antituberculous agents. III. (+)-2,2-(ethylenediimino)-di-1-butanol and some analogs. J. Med. Pharm. Chem. 5, 835–845 (1962).
Jia, L. Et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80–87 (2005).
Koul, A. Et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chem. Biol. 3, 323–324 (2007).
Petrella, S. Et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50, 2853–2856 (2006).
Lounis, N. Et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50, 3543–3547 (2006).
Deidda, D. Et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. 42, 3035–3037 (1998).
Arora, S. K., Sinha, N., Sinha, R. & Upadhyaya, R. S.U.S. Patent Application. US 2005/0256128 A1 (2005).
Casenghi, M. Development of new drugs for TB chemotherapy. Campaign for access to essential medicines [online], (2006).
Edwards, D. I. Mechanism of antimicrobial action of metronidazole. J. Antimicrob. Chemother. 5, 499–502 (1979).
Wayne, L. G. & Sohaskey, C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139–163 (2001).
Wayne, L. G. & Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054–2058 (1994).
Brooks, J. V., Furney, S. K. & Orme, I. M. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43, 1285–1288 (1999).
Ashtekar, D. R. Et al. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37, 183–186 (1993).
Nagrajan, K., Shankar, R. G., Rajappa, S., Shenoy, S. J. & Costa-Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity. Eur. J. Med. Chem. 24, 631–633 (1989).
Stover, C. K. Et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000).
Tyagi, S. Et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49, 2289–2293 (2005).
Nuermberger, E. Et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50, 2621–2625 (2006).
Matsumoto, M. Et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, 2131–2144 (2006).
Sasaki, H. Et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 49, 7854–7860 (2006).
Raether, W. & Hänel, H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol. Res. 90, S19–S39 (2003).
Brickner, S. J. Et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39, 673–679 (1996).
Zurenko, G. E. Et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839–845 (1996).
Colca, J. R. Et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278, 21972–21979 (2003).
Fortún, J. Et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56, 180–185 (2005).
Ntziora, F. & Falagas, M. E. Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review. Int. J. Tuberc. Lung Dis. 11, 606–611 (2007).
Park, I. N. Et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58, 701–704 (2006).
von der Lippe, B., Sandven, P. & Brubakk, O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) — a report of ten cases. J. Infect. 52, 92–96 (2006).
Sood, R., Rao, M., Singhal, S. & Rattan, A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int. J. Antimicrob. Agents 25, 464–468 (2005).
Fisher, J. F., Meroueh, S. O. & Mobashery, S. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105, 395–424 (2005).
Flores, A. R., Parsons, L. M. & Pavelka, M. S. Jr. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics. Microbiology 151, 521–532 (2005).
Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the Mycobacterium tuberculosis β-lactamase reveal its critical role in resistance to β-lactam antibiotics. Antimicrob. Agents Chemother. 50, 2762–2771 (2006).
Flores, A. R., Parsons, L. M. & Pavelka, M. S. Jr. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to β-lactam antibiotics. J. Bacteriol. 187, 1892–1900 (2005).
Chambers, H. F. Et al. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39, 2620–2624 (1995).
Chambers, H. F., Turner, J., Schecter, G. F., Kawamura, M. & Hopewell, P. C. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49, 2816–2821 (2005).
Rodloff, A. C., Goldstein, E. J. C. & Torres, A. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58, 916–929 (2006).
Chambers, H. F., Kocagoz, S., Sipit, T., Turner, J. & Hopewell, P. C. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26, 874–877 (1998).
Sauvage, E. Et al. Crystal structure of the Mycobacterium fortuitum class A β-lactamase: structural basis for broad substrate specificity. Antimicrob. Agents Chemother. 50, 2516–2521 (2006).
Lopez-Munoz, F. Et al. History of the discovery and clinical introduction of chlorpromazine. Ann. Clin. Psychiatry 17, 113–135 (2006).
Amaral, L., Kristiansen, J. E., Viveiros, M. & Atouguia, J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47, 505–511 (2001).
Hollister, L. E., Eikenberry, D. T. & Raffel, S. Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 81, 562–566 (1960).
Amaral, L., Kristiansen, J. E., Abebe, L. S. & Millet, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 38, 1049–1053 (1996).
Ratnakar, P. & Murthy, P. S. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol. Lett. 1, 73–76 (1992).
Reddy, M. V., Nadadhur, G. & Gangadharam, P. R. In-vitro and intracellular antimycobacterial activity of trifluoperazine. J. Antimicrob. Chemother. 37, 196–197 (1996).
Crowle, A. J., Douvas, G. S. & May, M. H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 38, 410–419 (1992).
Ordway, D. Et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 917–922 (2003).
Weinstein, E. A. Et al. Inhibitors of type II NADH: menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl Acad. Sci. USA 102, 4548–4553 (2005).
Xie, Z., Siddiqi, N. & Rubin, E. J. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 49, 4778–4780 (2005).
Bate, A. B. Et al. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg. Med. Chem. Lett. 17, 1346–1348 (2007).
Madrid, P. B., Polgar, W. E., Toll, L. & Tanga, M. J. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg. Med. Chem. Lett. 17, 3014–3017 (2007).
Schatz, A., Bugie, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66–69 (1944).
Schatz, A., Bugie, E. & Waksman, S. A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc. Soc. Exp. Biol. Med. 57, 244–248 (1944).
Kingston, W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J. Hist. Med. Allied Sci. 60, 218–220 (2005).
Pettersen, E. F. Et al. UCSF chimera — a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Wright, D. H., Brown, G. H., Peterson, M. L. & Rotschafer, J. C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46, 669–683 (2000).
McIlleron, H. Et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents. Chemother. 50, 1170–1177 (2006).
Berning, S. E. & Peloquin, C. A. In Antimicrobial Chemotherapy (eds Yu, V. L., Merigan, T. C., Barriere, S. & White, N. J.) 663–668 (Williams and Wilkins, Maryland, 1998).
Doluisio, J. T., Dittert, L. W. & LaPiana, J. C. Pharmacokinetics of kanamycin following intramuscular administration. J. Pharmacokinet. Biopharm. 1, 253–265 (1973).
Adamis, G. Et al. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Int. J. Antimicrob. Agents 23, 144–149 (2004).
Tuberculosis Isn't Gone: A Tale Of TB In The U.S. Today
Not all states require such training, but Dodie knows firsthand how important it can be. "I trained a young lady who said she had only once come across anyone with TB and didn't think it was still a problem. So, I told her about my daughter who is living proof that isn't true."
TB is caused by the bacterium Mycobacterium tuberculosis. It usually attacks the lungs, but TB bacteria can go after any part of the body. Not everyone infected with tuberculosis becomes sick, so TB is split into two categories:
Latent TB infection cannot be spread to others and individuals with latent TB do not have symptoms. While TB disease can be spread to others through the air when a person with active TB disease coughs or talks and others breathe in the bacteria.
Most people think of tuberculosis as a disease that no longer plagues our world, but it isn't gone. Though it is less common in the U.S. Than it was at the turn of the 20th century, the CDC estimates that there are 13 million people in the United States living with inactive TB. Without treatment, 1 in 10 of them will become sick with active TB disease, which is then highly contagious. In 2022, there were over 8,000 cases of TB in the United States, and TB was the second most infectious killer after COVID-19. Today, TB remains the 13th leading cause of death worldwide. There are options for treating latent TB infection to prevent getting TB disease later as well as treatment regimens for active TB disease that take several months. A healthcare provider will decide the appropriate treatment option. Successful completion of treatment is important to cure TB disease and minimize the spread to others. Anyone with either symptoms of TB or a positive TB test result should be evaluated by a healthcare provider for TB disease.
TB elimination in the United States is still the goal and will require efforts to diagnose and treat TB disease and latent TB infection, especially in communities at increased risk. Learn more at Lung.Org/tuberculosis.
Bharat Biotech Begins Clinical Trial Of Tuberculosis Vaccine MTBVAC In India
Hyderabad: Clinical trials of MTBVAC, the Spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, have been started in India, the most populated country in the world and the one with the highest number of cases of this infectious disease.
The trials are carried out by Bharat Biotech in close collaboration with Biofabri. Trials to evaluate the safety and immunogenicity of MTBVAC have started with a pivotal safety, immunogenicity and efficacy trial planned to start in 2025.
After more than three decades of research, Esteban Rodriguez, CEO of Biofabri says, "It is a giant step to test in adults and adolescents in the country where 28% of the world's TB cases accumulate and concludes that more effort and funding is needed to combat TB, which remains one of the world's leading infectious causes of death, especially in India."
Dr. Krishna Ella, Executive Chairman Bharat Biotech added, "Our quest for a more effective vaccine against Tuberculosis received a big boost, with clinical trials in India. Our goal to develop TB vaccines to prevent disease in adults and adolescents has taken a big step. We are honoured to partner with BioFabri, Dr. Esteban Rodriguez and Dr. Carlos Martin in this noble effort to reinvent TB vaccines."
As per the release, the MTBVAC vaccine has passed several milestones before entering clinical trials in India. The first is that after the recent completion of a Phase2 dose finding trial, a double-blind, controlled Phase3 clinical trial in newborns has started in 2023, comparing the vaccine with the current BCG vaccine. 7,000 newborns from South Africa, 60 from Madagascar and 60 from Senegal will be vaccinated. To date, more than 1,900 babies have been vaccinated. The aim is to assess the immunogenicity and efficacy of MTBVAC which is administered intradermally to infants on the first day of life.
Vaccination began at a time of setback in the global fight against TB. Health restrictions imposed during the COVID-19 pandemic led to an increase in infections and a decrease in diagnosis and treatment. As a result, annual TB deaths have risen to over 1.6 million.
This Phase3 neonatal project, partially funded by the European Union through its EDCTP (European & Development Countries Clinical Trial Partnership) programme, is being coordinated by Biofabri, as part of a consortium that also includes the University of Zaragoza (Unizar), TuBerculosis Vaccine Initiative (TBVI), The University of Cape Town (UCT)/SATVI, Wits VIDA Health Consortium (WHC), Stellenbosch University (SUN-FAMCRU), Enhancing Care Foundation (ECF), Center de Recherche Biomedicale Espoir Pour La Santé (CRB-EPLS, Senegal) and Institut Pasteur de Madagascar (IPM).
"Another important milestone is that after completing a dose escalation trial in HIV uninfected adults, a Phase2 study in HIV infected adults has started in 2024 to determine whether MTBVAC is safe in this population. This ongoing trial at 16 sites in South Africa – involving the vaccination of 276
Comments
Post a Comment